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Familial hypercholesterolaemia (FH) is a 
relatively common genetic disorder, with 
affected individuals exhibiting a lifelong 
elevation of plasma low- density lipopro-
tein (LDL) cholesterol and a marked 
tendency to premature atherosclerosis and 
early- onset cardiovascular disease (CVD). 
However, unlike most genetic disorders, 
FH is wholly treatable, especially following 
the widespread availability of potent lipid- 
lowering agents such as statins. Indeed, 
early and sustained therapy to lower LDL 
cholesterol can normalise this risk and 
prevent premature CVD.
With such enormous potential to 
prevent premature CVD, it is surprising 
then that only 7% of patients with FH are 
believed to have been identified in the UK. 
The picture is similar in many countries. 
In England, the NHS Long Term Plan 
has recently prioritised finding more of 
these undiagnosed patients and offering 
them treatment.1 Yet, the task of finding 
these people and their families, many of 
whom may be otherwise well, is enor-
mously challenging for a multitude of 
reasons, one of which is lack of awareness 
of the diagnosis. The situation could be 
improved by supporting primary care to 
identify those with high cholesterol levels 
and clinical features of FH, offering them 
an evaluation to confirm diagnosis before 
moving on to find their relatives, half of 
whom may carry the same mutation.
IDENTIFYING FH IN PRIMARY CARE 
USING CURRENT INFRASTRUCTURE
Brett et al in their study have shown that 
by simply using the current infrastruc-
ture of general practice, those affected by 
this condition can be successfully identi-
fied and treated.2 The primary care elec-
tronic health record (EHR) is of course 
the key game changer, enabling swift 
identification of people in whom the diag-
nosis may be likely. Several variations to 
the approach of using EHR to identify 
FH cases have been described as shown 
in figure 1. Options include systematically 
searching the records using established 
diagnostic criteria, such as Dutch Lipid 
Clinic Network (DLCN) criteria as used in 
the TARB- Ex tool2 or novel case- finding 
tools, such as FAMCAT.3 In parallel, 
electronic searches could create patient- 
specific computer reminders which alert 
the general practitioner (GP) opportunis-
tically when a patient at increased risk of 
FH is seen.4
Using EHR searches to identify patients 
at increased risk is a well- established case 
finding approach in primary care; for 
example, atrial fibrillation search tools 
have been used to identify stroke risk in 
affected patients leading to an increase 
in rates of anticoagulation.5 Further-
more, with the NHS health checks, more 
people have had their cholesterol profiles 
measured, along with discussions about 
cardiovascular risk in primary care, 
meaning this approach is well suited for 
FH identification.6 Clearly, the infrastruc-
ture is there to identify these individuals, 
but there are still important hurdles to 
overcome.
CHALLENGES FOR PRIMARY CARE FH 
IDENTIFICATION
First, the EHR searches are only as good 
as the data the records have captured. 
Cholesterol levels on their own are not 
sufficient to find patients with FH, and 
other information, such as a family history 
of premature CVD or hypercholestero-
laemia and physical signs, particularly 
tendon xanthoma, is needed to estimate 
the probability of FH. Currently, these 
are often poorly recorded or omitted 
altogether. Until this is resolved, EHR 
searches at best will only find people with 
a modestly high possibility of FH, thus 
necessitating a second step of formal clin-
ical assessment of this targeted group.
Herein lies the next challenge as demon-
strated by Brett et al, the question of 
motivation. Patients need to be contacted 
and assessed when they are not seeking 
healthcare, for a condition that has no 
symptoms or immediate perceived threat 
attached to it and a topic around which 
there is an emotive response in the media. 
Unsurprisingly, as with other primary care 
FH studies, Brett et al found a significant 
proportion of patients failed to attend for 
these assessments.2 4 Cholesterol, unlike 
blood pressure, has failed to trigger a 
sense of urgency or importance, which 
affects not only the public’s behaviour but 
also that of clinicians. Increasing educa-
tion among clinicians, as well as raising 
public awareness of the condition and the 
risk it entails, therefore has to go hand in 
hand with any case finding approach. In 
that regard, Brett et al show some promise 
in that educating GPs about FH seemed to 
improve management.
WHERE NEXT FOR CASE FINDING IN 
PRIMARY CARE?
Assuming the quality of records remains 
as they are for the foreseeable future, 
while public and clinician engagement 
and education may be improved, how 
can primary care better identify patients 
with FH? The key next step is a clinical 
assessment of this targeted at- risk popula-
tion, but who would deliver this in a busy 
general practice? Unlike the approach 
from Brett et al, it is unlikely that outside 
rural Australia, most GPs would have time 
to invite and assess hundreds of patients. 
An alternative is to involve other health-
care practitioners in primary care, such 
as healthcare assistants, practice- based 
pharmacists and nurses, to take on the 
task of evaluating patients for FH. Clin-
ical nurse specialists for FH are highly 
skilled at this clinical assessment, yet they 
are few and far between and employing 
them for this role would be expensive, but 
they could take on a more advisory role 
to support the relevant healthcare prac-
titioners in each practice, perhaps with 
virtual reviews of more challenging cases. 
Thereafter, once cases with higher likeli-
hood are identified, they could be referred 
for specialist evaluation, genetic testing 
and management in secondary care. 
This type of model with close primary 
and secondary care interaction has been 
successfully deployed for conditions such 
as atrial fibrillation.5 Whatever pathway 
is developed needs to consider the target 
population from the outset to prevent 
perpetuating inequalities.7
Given the central role of genetics in 
making a diagnosis of FH and permit-
ting cascade testing, a further innova-
tion thrown into the mix could be for 
GPs to offer genetic testing early on, 
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once patients meeting a certain diag-
nostic threshold are identified (eg, 
DLCN score over 5). However, with 
the introduction of more advanced 
next- generation sequencing, the inter-
pretation of the genetic results is even 
more challenging, especially when vari-
ants that are not clearly disease causing 
(variants of unknown significance 
(VUSs)) are identified. These VUSs 
still need referral for further investiga-
tion, but the primary care professional 
would need to explain the uncertainty 
and offer some degree of genetic coun-
selling. Furthermore, where a genetic 
mutation is not identified (~20% to 
30% of FH cases) and instead minor 
variations in several genes are found, 
also known as polygenic hypercholes-
terolaemia, GPs would need to know 
how to explain these results and manage 
the clinical phenotype.
The key role of genetic testing, of 
course, is to find a mutation that can 
be used for cascade testing and to find 
relatives who may or may not have very 
high levels of cholesterol. Brett et al 
have also suggested that cascade testing 
may be offered through primary care, 
noting each FH confirmed individual 
may identify up to five other relatives 
that may benefit from FH assessment. 
Caring for families is the foundation of 
general practice, and this approach may 
still hold in rural areas where several 
generations live locally. However, 
with population mobility, this is less 
likely to be the case especially in more 
urban areas. Under these circum-
stances, general practice- based cascade 
testing is impractical, other than GPs 
possibly supporting indirect cascade 
testing. The latter involves relatives 
at risk of FH, contacted through the 
affected individual rather than directly 
by the specialist. An alternative is to 
have community- based nurse specialists 
offering cascade testing across groups 
of practices.
Whether genetic testing is offered by 
GPs or in lipid clinics, ultimately a key 
requirement for successfully finding 
FH cases at scale is for centralised and 
national registries of patients with FH 
to monitor the success of case finding 
efforts but also to enable cascade 
testing nationally through pedigree- 
based systems, such as PASS software. 
Such a national database has been setup 
in Australia, but this is lacking in many 
nations, including the UK. However, 
efforts are ongoing to develop this.
CONCLUSION
Ultimately, successfully identifying the 
thousands of people with FH in the UK 
and abroad will require a system- wide 
approach from opportunistic identi-
fication at routine health encounters, 
systematic case finding in primary 
care, screening people at the time of a 
premature CVD event to child–parent 
screening and cascade testing. Brett et 
al have shown that primary care has 
the infrastructure and ability to iden-
tify many individuals with possible FH 
in their practices, using searches of 
general practice EHRs as a key starting 
point. Our challenge is to organise our 
primary healthcare teams and pathways 
to convert those in whom we have a 
high index of suspicion to a firm diag-
nosis of FH and to initiate appropriate 
management.8 It is at this point of clin-
ical assessment that primary care needs 
the most support from specialists, in 
particular, community- based FH nurses. 
Thus, although many patients with FH 
may be hidden in primary care, only 
a team effort can successfully uncover 
them and in the process save lives.
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Figure 1 Pathway to identification of FH from primary care. CVD, cardiovascular disease; DLCN, Dutch Lipid Clinic Network; FH, familial 
hypercholesterolaemia; GP, general practitioner; HCA, healthcare assistant; LLT, lipid- lowering treatment; VUS, variant of unknown significance.
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